Can a Brain-Targeting drug silence the relentless itch of dialysis?

NCT ID NCT07769073

NEW Not yet recruiting Symptom relief Sponsor: Indonesia University Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This trial tests whether nalfurafine, an oral drug that acts on opioid receptors in the body, can reduce the severe itching that often plagues people with chronic kidney disease who are on hemodialysis. Researchers will compare the drug against a placebo in adults aged 18 to 65 who have had moderate to severe itching despite standard care. The main goal is to see if nalfurafine lowers itch intensity, while also checking for any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nalfurafine hydrochloride, an oral drug that targets opioid receptors to reduce itching
What this could lead to: If effective, nalfurafine could offer a new, targeted way to relieve severe itching in dialysis patients, improving their comfort and quality of life.
What could go wrong: This is a small, early-stage trial, so results may not apply broadly. The drug may cause side effects or fail to outperform a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE ASSOCIATED PRURITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE ASSOCIATED PRURITUS END STAGE RENAL DISEASE ON DIALYSIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.